公开(公告)号：US20160304513A1

公开(公告)日：2016-10-20

申请号：US15101089

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/506 ,  A61K31/437

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506

Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20190100526A1

公开(公告)日：2019-04-04

申请号：US16086414

申请日：2017-03-31

Applicant: UCB Biopharma SPRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Louis Robert Deligny ,  Jag Paul Heer ,  Helen Tracey Horsley ,  Sophie Jadot ,  Jean Keyaerts

IPC: C07D487/22

Abstract: A series of substituted fused hexacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20190119302A1

公开(公告)日：2019-04-25

申请号：US16086418

申请日：2017-03-31

Applicant: UCB Biopharma SPRL ,  Sanofi

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer

IPC: C07D519/00 ,  C07D487/22

Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20190100525A1

公开(公告)日：2019-04-04

申请号：US16086408

申请日：2017-03-31

Applicant: UCB Biopharma SPRL ,  Sanofi

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer ,  Jean Keyaerts ,  Luce Elsa Lepissier ,  Martin Alexander Lowe

IPC: C07D487/18

Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US09926313B2

公开(公告)日：2018-03-27

申请号：US15101089

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/506

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506

Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.